Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Spero Therapeutics, Inc. | spro-ex322_6.htm |
| EX-32.1 - EX-32.1 - Spero Therapeutics, Inc. | spro-ex321_11.htm |
| EX-31.2 - EX-31.2 - Spero Therapeutics, Inc. | spro-ex312_13.htm |
| EX-31.1 - EX-31.1 - Spero Therapeutics, Inc. | spro-ex311_14.htm |
| EX-21.1 - EX-21.1 - Spero Therapeutics, Inc. | spro-ex211_7.htm |
| EX-10.13 - EX-10.13 - Spero Therapeutics, Inc. | spro-ex1013_338.htm |
| EX-10.12 - EX-10.12 - Spero Therapeutics, Inc. | spro-ex1012_337.htm |
| EX-10.6 - EX-10.6 - Spero Therapeutics, Inc. | spro-ex106_372.htm |
| EX-4.3 - EX-4.3 - Spero Therapeutics, Inc. | spro-ex43_371.htm |
| 10-K - 10-K - Spero Therapeutics, Inc. | spro-10k_20191231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-228661) and Form S-8 (Nos. 333-230283, 333-230281, and 333-222060) of Spero Therapeutics, Inc. of our report dated March 16, 2020 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 16, 2020